BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yan Z, Yang K, Tang X, Bi Y, Ding Y, Deng M, Xia D, Zhao Y, Chen T, Wang F. Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis. Journal of Immunology Research 2022;2022:1-10. [DOI: 10.1155/2022/3851604] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
Number Citing Articles
1 Zhai B, Sun J, Shi Y, Zhang X, Zou J, Cheng J, Fan Y, Guo D, Tian H. Review targeted drug delivery systems for norcantharidin in cancer therapy. J Nanobiotechnol 2022;20:509. [DOI: 10.1186/s12951-022-01703-3] [Reference Citation Analysis]
2 Wang CH, Wu HC, Hsu CW, Chang YW, Ko CY, Hsu TI, Chuang JY, Tseng TH, Wang SM. Inhibition of MZF1/c-MYC Axis by Cantharidin Impairs Cell Proliferation in Glioblastoma. Int J Mol Sci 2022;23. [PMID: 36499054 DOI: 10.3390/ijms232314727] [Reference Citation Analysis]
3 Liu Q, Sun H, Li X, Sheng H, Zhu L. Strategies for Solubility and Bioavailability Enhancement and Toxicity Reduction of Norcantharidin. Molecules 2022;27. [PMID: 36431851 DOI: 10.3390/molecules27227740] [Reference Citation Analysis]
4 Wang S, Song Y, Ma J, Chen X, Guan Y, Peng H, Yan G, Tang R. Dynamic crosslinked polymeric nano-prodrugs for highly selective synergistic chemotherapy. Asian J Pharm Sci 2022;17:880-91. [PMID: 36600901 DOI: 10.1016/j.ajps.2022.09.004] [Reference Citation Analysis]
5 Wang N, Pei B, Yuan X, Yi C, Wiredu Ocansey DK, Qian H, Mao F. Emerging roles of mesenchymal stem cell-derived exosomes in gastrointestinal cancers. Front Bioeng Biotechnol 2022;10:1019459. [DOI: 10.3389/fbioe.2022.1019459] [Reference Citation Analysis]